EDITED BY C. GLEN MAYHALL, MD MURRAY D. BATT, MD EDWARD S. WONG, MD

SHEA News

THE SOCIETY FOR HOSPITAL EPIDEMIOLOGY OF AMERICA

PRESIDENT
PRESIDENT-ELECT
VICE PRESIDENT
PAST PRESIDENT
SECRETARY

Peter A Gross, MD/Hackensack, New Jersey Bryan P. Simmons, MD/Memphis, Tennessee William J. Mat-tone, MD/Atlanta, Georgia Donald E. Craven, MD/Boston, Massachusetts Dale N. Gerding, MD/Chicago, Illinois TREASURER COUNCILOR COUNCILOR COUNCILOR COUNCILOR Elias Abrutyn, MD/Philadelphia, Pennsylvania Michael D. Decker, MD/Nashville, Tennessee Leigh G. Donowitz, MD/Charlottesville, Virginia Timothy W. Lane, MD/Greensboro, N. Carolina H. Gunner Deery, II, MD/Petoskey, Michigan

Varicella Vaccine on the Horizon

Contrary to what you may have read in the newspaper or heard on the radio, as of press time, varicella vaccine has not yet been approved by the Food and Drug Administration (FDA). The FDA's Advisory Committee on Vaccines and Related Biological Products at its meeting on January 28, 1994, told the FDA that it considered the data sufficient to support the manufacturer's claims that the varicella vaccine is safe and effective for children and for adults. Since Merck is not pursuing an indication for use of this vaccine in immunocompromised persons, this issue was not addressed, although there are ongoing studies of the vaccine in

human immunodeficiency virusinfected persons. On February 23-24, the Advisory Committee on Immunization Practices (ACIP) considered draft guidelines for usage of this product, pending FDA action on licensure. It is expected that the final Guidelines will recommend one dose of vaccine to infants between age 12 and 18 months, preferably with measles-mumps-rubella, and a "catch-up" dose for children younger than 13 years who lack a reliable history of chickenpox. After age 13, a two-dose schedule, separated by 4 to 8 weeks, likely will be advised for adolescents and adults without a reliable history of chickenpox. ACIP will be

recommending that susceptible (immunocompetent) healthcare workers be immunized using the two-dose schedule. Whether or not to test healthcare workers for varicella susceptibility, or to consider those with a negative or uncertain history as susceptible, will be guided by individual organizations' costs for vaccine versus diagnostic testing. Routine serologic testing of vaccinees after two doses will not be advised because of the 99% efficacy of the two-dose schedule. However, if a vaccinee incurs a documented exposure to chickenpox, consideration should be given to serologic testing for immunity.

SHEA/CDC/AHA Training Course in Hospital Epidemiology

The next SHEA/CDC/AHA
Training Course in Hospital
Epidemiology will be held May
7-10, 1994, at the Omni Shoreham
Hotel in Washington, DC. The
course provides an intensive
training program for those who
have responsibility for hospital
epidemiology and infection control
programs. The course is
sponsored by three of the nation's
most prestigious healthcare
organizations dedicated to
continuous quality improvement

in infection control and the application of epidemiology within the hospital setting.

The distinguished faculty for this course includes Martin S. Favero, PhD, and William J. Mar-tone, MD, from the Hospital Infections Program at the Centers for Disease Control and Prevention; Jonathan Freeman, MD, ScD, from the Harvard School of Public Health; Donald A. Goldmann, MD, from The Children's Hospital in Boston;

Robert W. Haley, MD, from the University of Texas Southwestern Medical Center in Dallas; David K. Henderson, MD, from the Clinical Center at the National Institutes of Health; John E. McGowan Jr, MD, from Grady Health Systems in Atlanta; Gina Pugliese, RN, MS, from the American Hospital Association; and Robert A. Weinstein, MD, from Michael Reese Hospital and Medical Center in Chicago.

The course is for hospital

epidemiologists, infection control practitioners, and others who are looking for a course that will provide the most current information concerning infection control practices and epidemiological methods in healthcare. This fundamental program will provide opportunities to find solutions to

real situations that will occur in the hospital setting. Intensive problem-solving sessions are supplemented with lectures and seminars presented by leading authorities.

Those interested in attending this course should register as soon as possible since, in the past, applicants for the course usually have exceeded the spaces available. Persons who would like to register for the course should contact the SHEA Meetings Department, 875 Rings Highway, Suite 200, Woodbury, NJ 08096. Telephone (609) 845-1720; FAX (609) 853-0411.

SHEA Elects New Officers

The newly elected officers for 1995 were announced at the business meeting at the Fourth Annual Meeting of the Society in New Orleans last month. Robert A. Weinstein, MD, from Michael Reese Hospital and Medical Center in Chicago, was elected vice president and will serve as President in 1997. Dr. Weinstein will have a 4-year commitment (vice president in 1995, president elect in 1996, president in 1997, and past president in 1998).

John W. Froggatt III, MD, hospital epidemiologist at the

Johns Hopkins Hospital in Baltimore, was elected to the position of academic councilor for the 2-year period 1995-1997. Edward S. Wong, MD, hospital epidemiologist at the McGuire Veterans Affairs Hospital in Richmond, was elected to the position of practice councilor also for the same period.

We congratulate our new officers on being elected by their peers to positions of trust and responsibility. We look forward to them joining the SHEA Board in January 1995.

Brief items of interest for the SHEA News or Newsletter may be sent to C. Glen Mayhall, MD, SHEA, Newsletter Editor, Division of Infectious Diseases, Route 1092; The Former Shriner's Burns Bldg, Room 2-64B; University of Texas Medical Branch; Galveston, TX, 77555-1092; FAX (409) 772-6527. Copy should be typed, double-spaced, and should not exceed five pages.